Desktop tool for converting MAIA microperimetry outputs into interactive 3D retinal sensitivity visualisations.
Microperimetry-based endpoints improved patient eligibility and detected treatment efficacy in a larger proportion of RPGR gene therapy trial participants than low luminance visual acuity.
Mesopic microperimetry was recommended as a stable and reliable outcome measure in inherited retinal disease, while scotopic microperimetry was limited by poorer reliability and floor effects in this cohort.